USPSTF recommends offering risk-reducing drugs (e.g., tamoxifen, raloxifene, or aromatase inhibitors) to women at increased risk for breast cancer and low risk for adverse drug effects (Grade B, high certainty that net benefit is moderate or moderate certainty that net benefit is moderate to substantial). USPSTF recommends against routine use of risk-reducing drugs in women who are not at increased risk for breast cancer (Grade D, moderate or high certainty that there is no net benefit or harms outweigh benefits).